NouvNeu001 Achieves Milestone with Successful Dosing of First Patient, Signaling Smooth Progress in iRegene Therapeutics' Multicenter Clinical Trial for Innovative Novel Parkinson's Disease Therapy
- Written by PR Newswire
WUHAN, China, Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period.
It is reported that the multicenter, open-label...














